Physician profile
Sara Lee
NPI 1871210278
$1,138.87
in general payments reported to CMS, 2019-2025
14 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $441 · 2024: $283 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $397.53 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $207.99 | 2023-2024 | Invega Sustenna |
| Abbvie INC. | $127.00 | 2023-2025 | |
| Adc Therapeutics America, INC. | $109.14 | 2025 | |
| Gilead Sciences, INC. | $60.62 | 2024 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.18 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $36.86 | 2023-2025 | Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $32.67 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $27.32 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $24.64 | 2023 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $22.68 | 2024 | Breztri |
| Novavax INC | $20.79 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Sanofi Pasteur INC. | $19.76 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.